The National Human Genome Research Institute is offering a grant opportunity to support research in novel technology innovation and early development in the field of Nucleic Acid Sequencing. This initiative aims to redirect NHGRI’s focus towards advancements in sequencing technology. Interested applicants are encouraged to form collaborations and develop projects in preparation for the anticipated Funding Opportunity Announcement to be released in the winter of 2021, with applications due in the summer of 2021. The closing date for submissions is February 1, 2023.
Opportunity ID: 332475
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-HG-21-008 |
| Funding Opportunity Title: | Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.172 — Human Genome Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 30, 2021 |
| Last Updated Date: | Mar 30, 2021 |
| Original Closing Date for Applications: | Feb 01, 2023 |
| Current Closing Date for Applications: | Feb 01, 2023 |
| Archive Date: | Mar 09, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The National Human Genome Research Institute intends to promote a new initiative by publishing a Request for Applications to solicit R43/R44 applications for research in the area of Transformative Nucleic Acid Sequencing Technology Innovation and Early Development: The purpose of the RFA is to refocus and emphasize NHGRIs investment in nucleic acid sequencing technology on novel technology innovation and early development. This Notice is being provided to allow potential applicants sufficient time to develop effective collaborations and responsive projects. The FOA is expected to be published in the winter of 2021 with an expected application due date in the summer of 2021. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-21-008.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 332475 Full Announcement-RFA-HG-21-008 -> RFA-HG-21-008-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00266252 | May 26, 2021 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00270959 | Dec 16, 2021 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278389 | Nov 14, 2022 | Feb 01, 2023 | View |
Package 1
Mandatory forms
332475 RR_SF424_2_0-2.0.pdf
332475 PHS398_CoverPageSupplement_5_0-5.0.pdf
332475 RR_OtherProjectInfo_1_4-1.4.pdf
332475 PerformanceSite_2_0-2.0.pdf
332475 RR_KeyPersonExpanded_2_0-2.0.pdf
332475 RR_Budget_1_4-1.4.pdf
332475 PHS398_ResearchPlan_4_0-4.0.pdf
332475 SBIR_STTR_Information_1_3-1.3.pdf
332475 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
332475 RR_SubawardBudget30_1_4-1.4.pdf
332475 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
332475 RR_SF424_5_0-5.0.pdf
332475 PHS398_CoverPageSupplement_5_0-5.0.pdf
332475 RR_OtherProjectInfo_1_4-1.4.pdf
332475 PerformanceSite_4_0-4.0.pdf
332475 RR_KeyPersonExpanded_4_0-4.0.pdf
332475 RR_Budget_3_0-3.0.pdf
332475 PHS398_ResearchPlan_4_0-4.0.pdf
332475 SBIR_STTR_Information_3_0-3.0.pdf
332475 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
332475 RR_SubawardBudget30_3_0-3.0.pdf
332475 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
332475 RR_SF424_5_0-5.0.pdf
332475 PHS398_CoverPageSupplement_5_0-5.0.pdf
332475 RR_OtherProjectInfo_1_4-1.4.pdf
332475 PerformanceSite_4_0-4.0.pdf
332475 RR_KeyPersonExpanded_4_0-4.0.pdf
332475 RR_Budget_3_0-3.0.pdf
332475 PHS398_ResearchPlan_5_0-5.0.pdf
332475 SBIR_STTR_Information_3_0-3.0.pdf
332475 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
332475 RR_SubawardBudget30_3_0-3.0.pdf
332475 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
